Clinical Case of a 36-Year-Old Man with Treatment-Resistant Paranoid Schizophrenia: Personalized Therapy Selection
Open Access
- 15 May 2022
- journal article
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in Personalized Psychiatry and Neurology
- Vol. 2 (1), 89-97
- https://doi.org/10.52667/2712-9179-2022-2-1-89-97
Abstract
Schizophrenia is a common and socially significant mental disorder that requires longterm use of antipsychotics (APs). Long-term use of APs increases the risk of developing adverse drug reactions (ADRs) and/or therapeutic resistance in some patients. This may be due to a genetically determined impairment of APs metabolism by cytochrome P450 enzymes and of Aps transport across the blood-brain barrier (BBB) and the cell membrane of APs target neurons in the brain. Pharmacogenetic testing (PGx) is a method to identify a group of patients with a high risk of developing AP-induced ADRs. The aim of the case report is to present the experience of using PGx in a 36-year-old patient with treatment-resistant schizophrenia and a medical history of AP-induced ADRs.Keywords
This publication has 12 references indexed in Scilit:
- How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?Frontiers in Genetics, 2020
- Structural and Mechanistic Principles of ABC TransportersAnnual Review of Biochemistry, 2020
- Problems and prospects for the implementation of pharmacogenetic testing in real clinical practice in the Russian FederationVestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery), 2020
- Pharmacogenetic aspects of the dopaminergic system in clozapine pharmacodynamicsZhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2020
- Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiologyNeuropharmacology, 2019
- Pharmacogenetics of schizophrenia in real clinical practice: a clinical caseNeurology, Neuropsychiatry, Psychosomatics, 2018
- Pharmacogenetics of drug–drug interaction and drug–drug–gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6Pharmacogenomics, 2017
- Psychotropic Medications Metabolized by Cytochromes P450 (CYP) 2D6 Enzyme and Relevant Drug InteractionsClinical Pharmacology & Biopharmaceutics, 2016
- Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4Current Drug Metabolism, 2008
- Cytochrome P450 Phenotyping/Genotyping in Patients Receiving AntipsychoticsClinical Pharmacokinetics, 2002